JD Health International Inc. (JD Health) approved the issuance of 834,412 new shares on 1 April 2026 to selected employees (excluding directors and senior management) under its Post-IPO Share Award Scheme. The allotment equals approximately 0.03% of the company’s total issued share capital as of the grant date. No consideration will be paid by the grantees.
The award will vest in tranches: • 112,580 shares over 0.25–3.25 years • 36,870 shares over 0.5–3.5 years • 684,962 shares over 1–4 years
A 22,417-share portion carries a vesting period shorter than 12 months because grants are made in batches for administrative purposes. No performance targets are attached.
A claw-back mechanism applies if an employee is dismissed without notice, convicted of an integrity-related offense, or engages in conduct detrimental to the group. The shares are also subject to any future recovery requirements arising from financial restatements.
Following the grant, 244.93 million shares remain available for future awards within the overall scheme limit of 312.71 million shares. The Hong Kong Stock Exchange previously approved the listing of shares issued under the scheme.
Administrative adjustments were simultaneously made to settle 43,750 previously granted award shares (granted on 1 July 2023, 1 April 2024, and 1 April 2025) with existing shares rather than newly issued shares; the terms of those grants remain unchanged.
The transaction does not trigger shareholder approval because it falls within the 1% individual limit for share-based awards in any 12-month period and none of the recipients is a director, chief executive, or substantial shareholder of JD Health.
Comments